CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin?
In the past decade, CHK2 has emerged as an important multifunctional player in the DNA-damage response signalling pathway. Parallel studies of the human CHEK2 gene have also highlighted its role as a candidate multiorgan tumour susceptibility gene rather than a highly penetrant predisposition gene for Li-Fraumeni syndrome. As discussed here, our current understanding of CHK2 function in tumour cells, in both a biological and genetic context, suggests that targeted modulation of the active kinase or exploitation of its loss in tumours could prove to be effective anti-cancer strategies.
Antoni
Laurent
L
Cancer Research UK Centre for Cancer Therapeutics, Institute of Cancer Research, Haddow Laboratories, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK.
Sodha
Nayanta
N
Collins
Ian
I
Garrett
Michelle D
MD
D000375:Aging / Q000473:pathology / Q000502:physiology; D000970:Antineoplastic Agents / Q000627:therapeutic use; D017209:Apoptosis; D064447:Checkpoint Kinase 2; D004249:DNA Damage; D004198:Disease Susceptibility / Q000201:enzymology; D006801:Humans; D009154:Mutation; D009369:Neoplasms / Q000201:enzymology* / Q000235:genetics / Q000503:physiopathology / Q000628:therapy; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*
D000970:Antineoplastic Agents; D064447:Checkpoint Kinase 2; C578634:CHEK2 protein, human; D017346:Protein Serine-Threonine Kinases